Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis.
Previous studies demonstrated that hepatic matrix metalloproteinase-9 (MMP-9) activity increased following cecal ligation and puncture (CLP) in rats, indicating liver injury in sepsis. The activity of MMP-9 in degrading extracellular matrix is controlled by activation of proenzymes and inhibition of tissue inhibitor of MMPs (TIMP-1). To further assess the proteolytic cascade imbalance in sepsis, hepatic MMP-9 and TIMP-1 expressions were examined in CLP rats. In this study, sepsis was induced in rats by CLP, and at 10 and 20 h after sepsis induction, liver samples were collected and MMP-2, MMP-9, and TIMP-1 gene and protein expressions were evaluated by real time PCR and Western blot analysis, respectively. Gene expression of MMP-9 was increased by 6.4-fold and 3.0-fold at 10 h and 20 h after CLP as compared to sham group, respectively. Likewise, MMP-9 protein expression was also significantly increased at both time points. In contrast, MMP-2 gene expression was not altered at 10 h and 20 h after CLP as compared to sham controls. Interestingly, TIMP-1 gene expression was elevated to 89-fold and 46-fold from sham levels at 10 h and 20 h after CLP, respectively. Similarly, TIMP-1 protein levels were also significantly increased at both time points. In addition, MMP-9/TIMP-1 protein ratio was lower at both 10 h and 20 h after CLP compared to sham rats. Results demonstrated an imbalance between MMP and TIMP, with a more evident role for MMP-9 than MMP-2, and high value of TIMP-1 was particularly evident in CLP rats. Our results indicate that MMP-9 and TIMP-1 expressions are increased and they may serve as useful markers to predict the outcome of sepsis.
Maitra
Subir R
SR
Department of Surgery, North Shore University Hospital and Long Island Jewish Medical Center, and The Feinstein Institute for Medical Research Manhasset, NY 11030, USA.
Jacob
Asha
A
Zhou
Mian
M
Wang
Ping
P
Acta Anaesthesiol Scand. 2003 Apr;47(4):407-10
12694137
Infect Immun. 2004 Jan;72(1):82-8
14688084
Crit Rev Oral Biol Med. 1993;4(2):197-250
8435466
Crit Care Med. 2005 Jul;33(7):1577-81
16003065
Chest. 1996 Dec;110(6 Suppl):273S-277S
8989164
Ann Med. 1999 Feb;31(1):34-45
10219712
Am J Med Sci. 1998 Dec;316(6):355-60
9856688
Scand J Infect Dis. 2006;38(10):867-72
17008230
Gastroenterology. 2002 Jan;122(1):188-201
11781293
Am J Respir Cell Mol Biol. 1997 Oct;17(4):519-28
9376127
Shock. 2004 Nov;22(5):478-81
15489642
J Surg Res. 2003 May 15;111(2):185-95
12850461
Crit Care. 2009;13(5):R158
19799791
Trends Immunol. 2001 Oct;22(10):571-9
11574282
Mol Cell Biochem. 2003 Sep;251(1-2):61-6
14575305
Shock. 2003 Sep;20(3):280-5
12923502
Ann N Y Acad Sci. 1994 Sep 6;732:11-21
7978784
Cardiovasc Res. 2005 Nov 1;68(2):318-26
16018991